Asclera Polidocanol Injection 0.5% (5 Ampules Containing 10 mg Per 2 mL) (RX)

Asclera (Polidocanol Injection 0.5%) is used for the treatment of uncomplicated spider veins (telangiectasia) and small varicose veins (reticular veins) in the legs. It functions as a sclerosing agent, working by irritating the inner lining of blood vessels, causing them to collapse and eventually be reabsorbed by the body. This treatment helps improve the appearance of affected veins, alleviating symptoms such as aching and swelling, and enhancing overall cosmetic results. Asclera provides a minimally invasive option for patients seeking relief from vein-related issues.

Asclera (Polidocanol) Injection 0.5% is a sclerosing agent used for the treatment of uncomplicated spider veins (telangiectasias) and small varicose veins (reticular veins) of the lower extremities. The solution works by damaging the endothelium of the vein, leading to fibrosis and vein closure. Each set includes 5 ampules, with each ampule containing 10 mg of polidocanol in 2 mL of solution, designed for professional use in medical practices specializing in vein treatments.

Details and Features:

• Concentration: Each ampule of Asclera contains a 0.5% solution of polidocanol, formulated for effectiveness in treating minor venous conditions.
  
• Packaging: Sold in sets containing 5 ampules, each providing 10 mg of polidocanol in 2 mL to accommodate multiple treatment sessions or multiple patients, subject to professional judgment.
  Use Indication: Effective for small varicose veins (1 to 3 mm in diameter) and spider veins (<1 mm) typically found on the legs—aesthetic improvements or symptom relief.
  
• Administration: The solution is injected directly into the targeted veins by a trained healthcare professional under appropriate aseptic conditions.
  
• Minimal Downtime: Generally well-received with minimal recovery time, allowing patients to resume most daily activities shortly after the procedure.

Mechanism of Action:

Polidocanol acts as a sclerosing agent by irritating the endothelium of vessels, causing them to collapse and form a fibrotic occlusion. This results in redirected blood flow through healthier veins and makes the treated veins less visible or invisible on the surface of the skin over time. The action ensures that the vessels are selectively targeted without impacting surrounding tissue significantly.

Warnings:

• Expert Use: Asclera should be administered only by healthcare professionals trained in sclerotherapy, to ensure correct site application and technique.
  
• Allergic Reactions: Known contraindications include patients with polidocanol sensitivity. Facilities should be prepared for emergency management of hypersensitivity responses.
  
• Not for Major Varicosities: It is not designed to treat larger varicose veins or patients with a history of thromboembolic disease, as these conditions might require different interventions.
  
• Pregnancy and Nursing: The safety profile has not been fully established in pregnant or nursing women, requiring a cautious approach to use.

Side Effects:

• Injection Site Reactions: Minor pain, swelling, and discoloration at the affected site are common, and generally resolve without intervention.
  
• Localized Effects: Possible irritation or bruising of the skin above the injection site, pigmentation disturbances, superficial thrombophlebitis, and temporary localized red welts.
  
• Serious Reactions: Although rare, side effects such as allergies, severe thrombosis, or neurologic symptoms like headaches or visual disturbance should trigger immediate medical evaluation.

Asclera Polidocanol Injection 0.5% provides a specialized treatment option for minor venous issues with an emphasis on professional administration and monitoring to achieve effective and safe outcomes, ensuring improved cosmetic appearance and relief from associated vein symptoms.